Intervention
Psilocybin
ClinicalTrials.gov intervention label
Clinical trials
31 shownPsilocybin Intervention for Veterans Overcoming Treatment-Resistant DepressionNCT07226232 · 2026-08-03
RECRUITINGEffect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive DisorderNCT07703722 · 2026-04-01
RECRUITINGPsilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung CancerNCT07216404 · 2026-01-01
RECRUITINGA Randomized Neuroimaging Trial of Psilocybin in DepressionNCT06072898 · 2025-05-28
RECRUITINGPsilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive DisorderNCT06592833 · 2025-02-25
RECRUITINGPsilocybin rTMS for Treatment Resistant DepressionNCT06132178 · 2025-01-10
RECRUITINGStudy of Psilocybin Assisted Psychotherapy to Address Fear of RecurrenceNCT06430541 · 2024-11-21
RECRUITINGOpen-Label Psilocybin Study in Transdiagnostic PopulationNCT06442423 · 2024-10-17
RECRUITINGThe Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderNCT06247839 · 2024-09-10
RECRUITINGPsilocybin Therapy for Depression in Parkinson's DiseaseNCT06455293 · 2024-08-19
RECRUITINGPsilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's DiseaseNCT04123314 · 2021-03-24
RECRUITINGNeuroplasticity Enhancement From Cognitive Training Reinforced by PsilocybinNCT07721467 · 2026-10-12
NOT_YET_RECRUITINGEffect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity MarkersNCT06746441 · 2024-12-01
COMPLETEDPsilocybin for Major Depressive DisorderNCT05675800 · 2024-01-01
WITHDRAWNPsilocybin in Co-occuring Major Depressive Disorder and Borderline Personality DisorderNCT05399498 · 2023-11-01
COMPLETEDTwo Doses of Psilocybin for the Treatment of MDD in Adults With CancerNCT05947383 · 2023-10-23
ACTIVE_NOT_RECRUITINGPET Synaptogenesis After Psilocybin In DEpression RecoveryNCT05601648 · 2023-07-01
WITHDRAWNPsilocybin-assisted CBT for DepressionNCT05227612 · 2023-06-27
COMPLETEDA Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderNCT05733546 · 2023-01-30
ACTIVE_NOT_RECRUITINGEffect of SSRIs on Response to Psilocybin TherapyNCT05594667 · 2023-01-01
WITHDRAWNThe Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDDNCT05381974 · 2022-09-15
WITHDRAWNThe Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationNCT05220410 · 2022-03-28
COMPLETEDPsilocybin for Treatment-Resistant DepressionNCT05029466 · 2021-11-19
COMPLETEDEfficacy and Safety of Psilocybin in Treatment-Resistant Major DepressionNCT04670081 · 2021-06-10
COMPLETEDPsilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderNCT04620759 · 2021-04-14
ACTIVE_NOT_RECRUITINGThe Effect of Psilocybin on MDD Symptom Severity and Synaptic DensityNCT04630964 · 2021-01-01
COMPLETEDThe Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive DisorderNCT04593563 · 2020-09-01
UNKNOWNA Study of Psilocybin for Major Depressive Disorder (MDD)NCT03866174 · 2020-01-23
COMPLETEDPsilocybin and DepressionNCT03380442 · 2018-09-01
UNKNOWNPsilocybin-assisted Group Therapy for Demoralization in Long-term AIDS SurvivorsNCT02950467 · 2018-01-05
COMPLETEDEffects of Psilocybin in Major Depressive DisorderNCT03181529 · 2017-08-10
COMPLETEDCommon conditions
Major Depressive Disorder17Depression6Treatment Resistant Depression3Depressive Disorder2Alcohol Use Disorder1Alzheimer Disease1Alzheimer's Disease1Anhedonia1Anxiety1Borderline Personality Disorder1Breast Cancer1Cancer1Depression - Major Depressive Disorder1Depressive Disorder, Major1Depressive Symptoms1Distress1Grief1Lung Non-Small Cell Carcinoma1Major Depression1MDD1Mild Cognitive Impairment1Mild Depression1Moderate Depression1OCD1Ovarian Cancer1
Leading sponsors
Johns Hopkins University3Khyber Medical University Peshawar2Washington University School of Medicine2Alan Davis1Brain and Cognition Discovery Foundation1Central Institute of Mental Health, Mannheim1COMPASS Pathways1Cybin Therapeutics Inc.1Icahn School of Medicine at Mount Sinai1Joshua Woolley1Joshua Woolley, MD, PhD1Maryland Oncology Hematology, PA1Massachusetts General Hospital1National Institute on Aging (NIA)1Section for Affective Disorders; Northern Stockholm Psychiatry1
Trial status mix
RECRUITING11
COMPLETED10
WITHDRAWN4
ACTIVE_NOT_RECRUITING3
UNKNOWN2
NOT_YET_RECRUITING1
Phase mix
PHASE223
PHASE14
PHASE33
EARLY_PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.